

THE BREAST CANCER
RESEARCH FOUNDATION, INC.

CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2025 and 2024

THE BREAST CANCER RESEARCH FOUNDATION, INC.

Contents

	<u>Page</u>
Independent Auditors' Report	1 - 2
Consolidated Financial Statements	
Statements of financial position as of June 30, 2025 and 2024	3
Statements of activities for the years ended June 30, 2025 and 2024	4
Statement of functional expenses for the year ended June 30, 2025 (with summarized financial information for the year ended June 30, 2024)	5
Statement of functional expenses for the year ended June 30, 2024	6
Statements of cash flows for the years ended June 30, 2025 and 2024	7
Notes to financial statements	8 - 26

INDEPENDENT AUDITORS' REPORT

The Board of Directors
The Breast Cancer Research Foundation, Inc.

Report on the Audit of the Financial Statements

Opinion

We have audited the financial statements of The Breast Cancer Research Foundation, Inc. (the "Foundation"), which comprise the consolidated statements of financial position as of June 30, 2025 and 2024, and the related consolidated statements of activities, functional expenses, and cash flows for each of the years then ended, and the related notes to the financial statements.

In our opinion, the accompanying financial statements present fairly, in all material respects, the consolidated financial position of The Breast Cancer Research Foundation, Inc. as of June 30, 2025 and 2024, and the consolidated changes in their net assets, and their cash flows for each of the years then ended, in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audits in accordance with auditing standards generally accepted in the United States of America ("GAAS"). Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of the Foundation and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Financial Statements

The Foundation's management is responsible for the preparation and fair presentation of these financial statements, in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Foundation's ability to continue as a going concern for one year after the date that the financial statements are available to be issued.

Auditors' Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with GAAS, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Foundation's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Foundation's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

EisnerAmper LLP

EISNERAMPER LLP
New York, New York
May 6, 2026



THE BREAST CANCER RESEARCH FOUNDATION, INC.

Consolidated Statements of Financial Position

	June 30,	
	<u>2025</u>	<u>2024</u>
ASSETS		
Cash and cash equivalents	\$ 89,082,207	\$ 72,935,937
Pledges receivable, net	21,302,221	33,777,545
Other receivables	562,235	788,347
Investments	105,562,070	88,515,733
Program-related investment (Note J)	999,991	-
Prepaid expenses and other assets	444,126	457,616
Right-of-use asset	2,028,039	2,699,754
Property and equipment, net	397,420	441,932
Security deposits	100,541	100,541
	<u>\$ 220,478,850</u>	<u>\$ 199,717,405</u>
LIABILITIES		
Accounts payable and accrued expenses	\$ 1,840,412	\$ 984,144
Grants payable, net	80,927,701	72,473,772
Lease liability	2,213,263	2,946,720
	<u>84,981,376</u>	<u>76,404,636</u>
Commitments and Contingency (Note N)		
NET ASSETS		
Without donor restrictions:		
Undesignated – available for operations	<u>99,950,000</u>	<u>75,733,470</u>
With donor restrictions:		
Purpose restrictions	15,042,147	16,371,006
Time restricted for future periods	11,941,986	22,667,546
Perpetual in nature	<u>8,563,341</u>	<u>8,540,747</u>
Total net assets with donor restrictions	<u>35,547,474</u>	<u>47,579,299</u>
Total net assets	<u>135,497,474</u>	<u>123,312,769</u>
	<u>\$ 220,478,850</u>	<u>\$ 199,717,405</u>

See notes to financial statements.

THE BREAST CANCER RESEARCH FOUNDATION, INC.

Consolidated Statements of Activities

	Year Ended June 30,					
	2025			2024		
	Without Donor Restrictions	With Donor Restrictions	Total	Without Donor Restrictions	With Donor Restrictions	Total
Operating activities:						
Public support and revenue:						
Contributions of financial assets	\$ 72,122,302	\$ 5,422,222	\$ 77,544,524	\$ 76,275,470	\$ 14,527,770	\$ 90,803,240
Contributions of nonfinancial assets	6,821,188	-	6,821,188	1,394,558	-	1,394,558
Special events (net of direct benefits to donors of \$3,191,089 and \$3,017,929 in fiscal-years 2025 and 2024, respectively)	16,914,402	-	16,914,402	24,801,982	-	24,801,982
Total public support and revenue	<u>95,857,892</u>	<u>5,422,222</u>	<u>101,280,114</u>	<u>102,472,010</u>	<u>14,527,770</u>	<u>116,999,780</u>
Expenses:						
Program services	84,455,828	-	84,455,828	76,508,638	-	76,508,638
Management and general	7,565,231	-	7,565,231	4,789,628	-	4,789,628
Fund-raising	9,511,200	-	9,511,200	9,159,327	-	9,159,327
Total expenses	<u>101,532,259</u>	<u>-</u>	<u>101,532,259</u>	<u>90,457,593</u>	<u>-</u>	<u>90,457,593</u>
(Deficiency) excess of operating activities over expenses						
before net assets released from restrictions	(5,674,367)	5,422,222	(252,145)	12,014,417	14,527,770	26,542,187
Net assets released from restrictions	<u>18,502,087</u>	<u>(18,502,087)</u>	<u>-</u>	<u>9,769,984</u>	<u>(9,769,984)</u>	<u>-</u>
(Deficiency) excess of operating activities support and revenue over expenses	<u>12,827,720</u>	<u>(13,079,865)</u>	<u>(252,145)</u>	<u>21,784,401</u>	<u>4,757,786</u>	<u>26,542,187</u>
Non-operating activities:						
Net investment income	10,696,898	1,048,040	11,744,938	8,863,545	973,497	9,837,042
Grant refunds	700,194	-	700,194	44,065	-	44,065
Foreign currency losses	(77,916)	-	(77,916)	(24,681)	-	(24,681)
Other income	69,634	-	69,634	69,845	-	69,845
Change in net assets	<u>24,216,530</u>	<u>(12,031,825)</u>	<u>12,184,705</u>	<u>30,737,175</u>	<u>5,731,283</u>	<u>36,468,458</u>
Net assets, beginning of year	<u>75,733,470</u>	<u>47,579,299</u>	<u>123,312,769</u>	<u>44,996,295</u>	<u>41,848,016</u>	<u>86,844,311</u>
Net assets, end of year	<u>\$ 99,950,000</u>	<u>\$ 35,547,474</u>	<u>\$ 135,497,474</u>	<u>\$ 75,733,470</u>	<u>\$ 47,579,299</u>	<u>\$ 123,312,769</u>

See notes to financial statements.

THE BREAST CANCER RESEARCH FOUNDATION, INC.

**Consolidated Statement of Functional Expenses
Year Ended June 30, 2025**

(with summarized financial information for the year ended June 30, 2024)

	Program Services: Research	Supporting Services			Total	
		Management and General	Fund-raising	Total Supporting Services	Total	
					2025	2024
Grants awarded	\$ 65,975,695	\$ -	\$ -	\$ -	\$ 65,975,695	\$ 65,622,949
Founder's Fund grants awarded	5,972,158	-	-	-	5,972,158	4,681,161
Special events:						
Venue, food and beverages	-	-	1,677,669	1,677,669	1,677,669	1,509,921
Audio visual	-	-	759,007	759,007	759,007	767,100
Entertainment	-	-	191,198	191,198	191,198	214,523
Other direct event costs	-	-	563,215	563,215	563,215	526,385
Printing, postage and office expenses	-	-	519,058	519,058	519,058	471,365
Event management and production	-	-	738,052	738,052	738,052	303,493
Other	-	-	833,164	833,164	833,164	822,368
Salaries and employee benefits	4,756,873	3,928,960	3,106,824	7,035,784	11,792,657	10,627,920
Contracted services	237,607	343,771	251,318	595,089	832,696	215,495
Conferences and meetings	356,212	-	-	-	356,212	243,626
Professional fees	5,995,313	1,943,962	2,923,932	4,867,894	10,863,207	4,441,098
Occupancy	290,257	222,034	243,922	465,956	756,213	756,618
Telephone	16,116	80,604	35	80,639	96,755	51,558
Supplies	4,193	36,144	22,316	58,460	62,653	52,815
Printing, postage and office expenses	801,918	627,134	830,992	1,458,126	2,260,044	1,842,613
Increase in allowance for uncollectible accounts	-	307,581	-	307,581	307,581	178,876
Licenses	-	37,177	-	37,177	37,177	17,344
Total expenses before depreciation and amortization	84,406,342	7,527,367	12,660,702	20,188,069	104,594,411	93,347,228
Depreciation and amortization	49,486	37,864	41,587	79,451	128,937	128,294
Total expenses	84,455,828	7,565,231	12,702,289	20,267,520	104,723,348	93,475,522
Less: direct benefits to donors	-	-	(3,191,089)	(3,191,089)	(3,191,089)	(3,017,929)
Total expenses per consolidated statements of activities	\$ 84,455,828	\$ 7,565,231	\$ 9,511,200	\$ 17,076,431	\$ 101,532,259	\$ 90,457,593

See notes to financial statements.

THE BREAST CANCER RESEARCH FOUNDATION, INC.

**Consolidated Statement of Functional Expenses
Year Ended June 30, 2024**

	Program Services: Research	Supporting Services		Total Supporting Services	Total
		Management and General	Fund-raising		
Grants awarded	\$ 65,622,949	\$ -	\$ -	\$ -	\$ 65,622,949
Founder's Fund grants awarded	4,681,161	-	-	-	4,681,161
Special events:					
Venue, food and beverages	-	-	1,509,921	1,509,921	1,509,921
Audio visual	-	-	767,100	767,100	767,100
Entertainment	-	-	214,523	214,523	214,523
Other direct event costs	-	-	526,385	526,385	526,385
Printing, postage and office expenses	-	-	471,365	471,365	471,365
Event management and production	-	-	303,493	303,493	303,493
Other	-	-	822,368	822,368	822,368
Salaries and employee benefits	3,712,242	2,324,092	4,591,586	6,915,678	10,627,920
Contracted services	48,477	64,679	102,339	167,018	215,495
Conferences and meetings	243,626	-	-	-	243,626
Professional fees	1,183,280	1,165,782	2,092,036	3,257,818	4,441,098
Occupancy	264,816	257,995	233,807	491,802	756,618
Telephone	961	50,577	20	50,597	51,558
Supplies	3,441	42,110	7,264	49,374	52,815
Printing, postage and office expenses	702,782	644,427	495,404	1,139,831	1,842,613
Increase in allowance for uncollectible accounts	-	178,876	-	178,876	178,876
Licenses	-	17,344	-	17,344	17,344
Total expenses before depreciation and amortization	76,463,735	4,745,882	12,137,611	16,883,493	93,347,228
Depreciation and amortization	44,903	43,746	39,645	83,391	128,294
Total expenses	76,508,638	4,789,628	12,177,256	16,966,884	93,475,522
Less: direct benefits to donors	-	-	(3,017,929)	(3,017,929)	(3,017,929)
Total expenses per consolidated statements of activities	\$ 76,508,638	\$ 4,789,628	\$ 9,159,327	\$ 13,948,955	\$ 90,457,593

See notes to financial statements.

THE BREAST CANCER RESEARCH FOUNDATION, INC.

Consolidated Statements of Cash Flows

	Year Ended June 30,	
	2025	2024
Cash flows from operating activities:		
Change in net assets	\$ 12,184,705	\$ 36,468,458
Adjustments to reconcile change in net assets to net cash provided by operating activities:		
Depreciation and amortization	128,937	128,294
Unrealized gains on investments	(4,395,887)	(8,305,445)
Realized (gains) losses on investments	(1,118,063)	4,262,281
Donated securities	(4,597,865)	(2,834,458)
Proceeds from sale of donated securities	4,557,786	2,803,149
Increase in allowance for uncollectible accounts	307,581	178,876
Contributions - perpetual in nature	(350,000)	(477,835)
Noncash lease amortization	671,715	669,577
Changes in:		
Pledges receivable, net	12,167,743	(2,769,012)
Other receivables	226,112	(375,966)
Prepaid expenses and other assets	13,490	(352,214)
Accounts payable and accrued expenses	856,268	(470,179)
Grants payable, net	8,453,929	10,881,535
Lease liability	(733,457)	(731,319)
Net cash provided by operating activities	<u>28,372,994</u>	<u>39,075,742</u>
Cash flows from investing activities:		
Proceeds from sales of investments	25,588,381	68,125,980
Purchases of investments	(37,080,689)	(69,903,159)
Program-related investment made	(999,991)	-
Purchases of property and equipment	(84,425)	(13,498)
Net cash used in investing activities	<u>(12,576,724)</u>	<u>(1,790,677)</u>
Cash flows from financing activities:		
Repayment of Paycheck Protection Program loan	-	(103,621)
Contributions - perpetual in nature	350,000	477,835
Net cash provided by financing activities	<u>350,000</u>	<u>374,214</u>
Net increase in cash and cash equivalents	16,146,270	37,659,279
Cash and cash equivalents, beginning of year	<u>72,935,937</u>	<u>35,276,658</u>
Cash and cash equivalents, end of year	\$ 89,082,207	\$ 72,935,937
Supplemental disclosures of cash flow information:		
Donated non-financial assets	\$ 6,821,188	\$ 1,394,558
Interest paid	\$ -	\$ 2,323

See notes to financial statements.

THE BREAST CANCER RESEARCH FOUNDATION, INC.

Notes to Financial Statements June 30, 2025 and 2024

NOTE A - THE FOUNDATION AND ITS SIGNIFICANT ACCOUNTING POLICIES

[1] The Foundation:

The Breast Cancer Research Foundation, Inc. ("BCRF") is a New York not-for-profit organization, incorporated in 1993. The mission of BCRF is to prevent and cure breast cancer by advancing the world's most promising research. The Breast Cancer Research Foundation in Canada ("BCRF Canada") is an officially registered tax-exempt charity in Canada. Gains and losses from foreign currency translations are included in the statements of activities. BCRF is also the sole member of BCRF Ventures LLC, a limited liability, not-for-profit corporation organized in Delaware in November 2024 (see Note J). As these entities meet the criteria for consolidation, their financial statements are consolidated with those of BCRF (together, the "Foundation"). All inter-organization balances and transactions have been eliminated in consolidation.

The Foundation makes grants to fund breast cancer research at many internationally recognized, tax-exempt hospitals, medical centers, universities, and research organizations. Grant awards are based on proposals made by physicians, researchers, and other knowledgeable individuals, as recommended by the Foundation's Scientific Advisory Board and approved by the Board of Directors.

BCRF qualifies as a charitable organization as defined by Section 501(c)(3) of the Internal Revenue Code (the "Code") and, accordingly, is exempt from federal income taxes under Section 501(a) of the Code and from state and local income taxes under comparable laws. Since BCRF is publicly supported, contributions to the Foundation qualify for the maximum charitable-contribution deduction under the Code. BCRF Ventures LLC is considered to be a disregarded entity for tax purposes, and therefore, the activities of the LLC are reported in BCRF's compliance returns.

[2] Basis of accounting:

The consolidated financial statements have been prepared using the accrual basis of accounting and conform to accounting principles generally accepted in the United States of America ("U.S. GAAP"), as applicable to not-for-profit organizations.

[3] Use of estimates:

The preparation of consolidated financial statements in conformity with U.S. GAAP requires the Foundation's management to make estimates and assumptions that affect the reported amounts of assets, liabilities, public support and revenue and expenses and the disclosure of contingent assets and liabilities. Actual results may differ from those estimates.

[4] Cash and cash equivalents:

The Foundation considers all highly liquid investments, with maturities of three months or less when purchased, to be cash equivalents for financial statement reporting purposes. Cash and cash equivalents held as part of the Foundation's investment portfolio are reflected as investments in the consolidated statements of financial position.

THE BREAST CANCER RESEARCH FOUNDATION, INC.

Notes to Financial Statements June 30, 2025 and 2024

NOTE A - THE FOUNDATION AND ITS SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

[5] Investments and Program-Related Investments:

Investments:

The Foundation's investments in government and corporate obligations and mutual funds are reported at their fair values in the consolidated statements of financial position at each fiscal year-end based on quoted market prices.

These investments, in general, are subject to various risks, such as interest-rate, market, and credit risks. Due to the level of risk associated with certain investment vehicles, it is at least reasonably possible that changes in the values of those securities could occur in the near term, and that such changes could materially affect the amounts reported in the consolidated financial statements.

Investment transactions are recorded on a trade-date basis. Realized gains and losses on investments sold, and unrealized appreciation and depreciation on investments held, are reported in the consolidated statements of activities as increases or decreases in net assets without donor restrictions unless their use is restricted through donor stipulation. Realized gains and losses on investments are determined by comparison of the cost at the time of acquisition to the proceeds at the time of disposition. Unrealized gains and losses on investments are determined by comparing the investment's cost to the fair value at the end of each fiscal year. The earnings from dividends and interest are recognized when earned.

Investment expenses include the services of investment managers and custodians. The balances of investment management fees disclosed in Note C are those specific fees charged by the Foundation's various investment managers in each fiscal year; however, they do not include those fees that are embedded in various other investment transactions.

Donated securities are recorded at their estimated fair values on the dates of donation. The Foundation's policy is to sell donated securities immediately, and, accordingly, for purposes of the consolidated statements of cash flows, donated securities and the proceeds generated from their sale are included as operating activities.

Program-Related Investments:

The Foundation has a program-related investment in non-readily marketable securities which is an ownership interest in a privately held corporation for which market values are not readily obtainable (see Note J). Because of the complex management structure and nature of the underlying investment and the inherent uncertainty of the valuation of the investment, the Foundation monitors the position to be aware of changes in fair values (See Note C). The estimated values reported in the consolidated financial statements may differ from actual values had a ready market for the investment existed.

Due to the level of risk associated with this investment it is at least reasonably possible that a change in the value of this investment could occur in the near term and that such a change could materially affect the amount reported in the financial statements.

THE BREAST CANCER RESEARCH FOUNDATION, INC.

Notes to Financial Statements June 30, 2025 and 2024

NOTE A - THE FOUNDATION AND ITS SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

[6] Property and equipment:

Property and equipment are stated at their original costs at the dates of acquisition, or, if contributed, at their fair values at the dates of donation, net of accumulated depreciation and amortization. The Foundation capitalizes leasehold improvements and furniture and equipment with a cost of \$5,000 or more and a useful life greater than one year, whereas minor costs of repairs and maintenance are expensed as incurred. Depreciation of furniture and equipment is provided over the estimated useful life of five years, using the straight-line method. Leasehold improvements are amortized over the remaining lease term or the estimated life of the improvements, whichever is shorter.

Management evaluates the recoverability of the investment in long-lived assets on an ongoing basis when triggering events indicate that the fair value of the long-lived assets may be less than the carrying value and recognizes impairment in the year of determination. There were no triggering events during fiscal-years 2025 and 2024, requiring management to test for impairment that would require adjustment to property and equipment.

[7] Grants payable:

The Foundation records awards of unconditional research grants and Founder's Fund grants as expenses and liabilities after the approval by the Board of Directors, based upon the guidance and input of the Foundation's Scientific Advisory Board. Research grants are generally paid within one year. Unconditional grants not expected to be paid within the following year are reported at their discounted present values. The Foundation receives refunds from the underlying grantee institutions when a project is terminated before completion or when the underlying investigator moves to another institution. When the project is terminated, those funds are treated as income by the Foundation and are added to the funds available for future research grants. When an investigator changes institutions and the work previously funded will continue, the Foundation redistributes the unused funds to the investigator's new institution.

[8] Leases:

The Foundation determines if an arrangement is a lease at inception. For the Foundation's operating leases, a right-of-use ("ROU") asset represents the Foundation's right to use an underlying asset for the lease term and an operating lease liability represents an obligation to make lease payments arising from the lease. The ROU asset and lease liability are recognized at the lease commencement date based on the present value of lease payments over the lease term. Since the Foundation's lease agreements do not provide an implicit interest rate, the Foundation uses a risk-free rate based on the information available at the commencement date in determining the present value of the lease payments. Operating lease expense is recognized on a straight-line basis over the lease term, subject to any changes in the lease or expectations regarding the terms. Variable lease costs, such as operating costs, are expensed as incurred. There were no variable lease costs in either fiscal year.

THE BREAST CANCER RESEARCH FOUNDATION, INC.

Notes to Financial Statements June 30, 2025 and 2024

NOTE A - THE FOUNDATION AND ITS SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

[9] Net assets:

The net assets of the Foundation and changes therein are classified and reported as follows:

(i) *Net assets without donor restrictions:*

The Foundation's net assets without donor restrictions represent those resources that are available for current operations as there are no restrictions by donors as to their use.

(ii) *Net assets with donor restrictions:*

Net assets with donor restrictions represent those resources that are subject to donor-imposed restrictions, such as specific purposes and/or a specific period of time. Also included within net assets with donor restrictions are donor restrictions that are perpetual in nature and subject to the New York Prudent Management of Institutional Funds Act ("NYPMIFA"). These donors have stipulated that those resources be maintained in perpetuity, with the resultant income and net capital appreciation arising from the underlying assets be used in the satisfaction of the wishes of those donors. When a donor restriction expires, that is, when a stipulated time restriction ends, a purpose restriction is accomplished, or funds are appropriated through an action of the Board of Directors, net assets with donor restrictions are reclassified to net assets without donor restrictions and reported in the consolidated statements of activities as "net assets released from restrictions."

[10] Revenue recognition:

(i) *Contributions, gifts and pledges:*

Contributions to the Foundation are recognized as revenue upon the receipt of cash, unconditional pledges or other assets. Contributions are recorded as "with donor restrictions" if they are received with donor stipulations or time considerations as to their use. Conditional contributions are recorded when the conditions have been met. Contributions of assets other than cash are recorded at their estimated fair values at the dates of donation. Contributions to be received after one year are discounted at an appropriate interest rate, commensurate with the risk involved. The Foundation periodically assesses the collectability of its outstanding pledges and provides allowances for anticipated losses, if any, when necessary.

(ii) *Special events:*

A portion of the gross proceeds paid by attendees at special events held as fundraising activities represents contribution revenue, whereas the other portion serves as the payment of the direct costs of the benefits received by the attendee at the event. Special event income is reported net of the direct benefits to donors. Special event revenues, other than the contribution portion, applicable to a future year are recognized as revenue in the year the special event takes place.

THE BREAST CANCER RESEARCH FOUNDATION, INC.

Notes to Financial Statements June 30, 2025 and 2024

NOTE A - THE FOUNDATION AND ITS SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

[10] Revenue recognition: (continued)

(iii) *Donated goods and services (contribution of nonfinancial assets):*

From time-to-time, the Foundation receives various forms of gifts-in-kind, which are contributions of nonfinancial assets, including donated merchandise and scientific and legal services, and donated advertising services in the form of public service announcements (“PSAs”) across various media platforms. Contributions of non-financial assets are recorded at their estimated fair value on the date of receipt and reported as expenses when utilized. Donated goods are valued based upon estimates of fair value that would be received for selling the goods in their principal market, considering the condition and utility of the goods at the time of contribution. Donated services are recognized when they require specialized skills, are provided by individuals possessing those skills, and would otherwise need to be purchased by the Foundation. It is the Foundation's policy that contributions of nonfinancial assets are only utilized within operations to support the Foundation's mission and not monetized.

During fiscal year 2025, the recognition criteria for donated PSAs were met, as the Foundation exercised sufficient involvement in the development, timing, and use of the messaging and obtained control over the use of the donated advertising services. As a result, donated PSAs with an estimated fair value of approximately \$4,914,000 were recognized as contribution revenue and corresponding program expenses in the consolidated financial statements for the fiscal year ended June 30, 2025.

During fiscal year 2024, donated PSAs with an estimated fair value of approximately \$285,000 did not meet the criteria for revenue recognition, as the Foundation was not actively involved in determining or managing the content of the messages and did not have control over others' access to the associated benefits. Accordingly, the value of these PSAs was not recognized in the consolidated financial statements for that year.

[11] Measure of operations:

The Foundation includes in its definition of operations, all public support and revenue and expenses that are an integral part of its programs and supporting activities. Net investment income, refunds of grants awarded in prior years, foreign currency losses, and other income are recognized as part of the Foundation's non-operating activities.

[12] Functional allocation of expenses:

The costs of providing the Foundation's various programs and supporting services have been summarized on a functional basis in the consolidated statements of activities. The consolidated statements of functional expenses present expenses by functional and natural classification. Accordingly, direct costs have been functionalized within the program and supporting services, based on the nature of the expense. Indirect costs, including salaries and employee benefits, occupancy costs and depreciation have been allocated on the basis of time spent among employees.

[13] Income tax uncertainties:

The Foundation is subject to the provisions of the Financial Accounting Standard's Board (the “FASB”) Accounting Standards Codification (“ASC”) Topic 740, *Income Taxes*, relating to accounting and reporting for uncertainty in income taxes. Because of the Foundation's general tax-exempt status, management believes ASC Topic 740 has not had, and is not expected to have, a material impact on the Foundation's consolidated financial statements.

THE BREAST CANCER RESEARCH FOUNDATION, INC.

Notes to Financial Statements June 30, 2025 and 2024

NOTE A - THE FOUNDATION AND ITS SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

[14] Reclassification:

Certain amounts in the fiscal-year 2024 financial statements have been reclassified to conform to the presentation in the accompanying fiscal-year 2025 financial statements. These reclassifications had no effect on the change in net assets or total net assets previously reported.

NOTE B - PLEDGES AND OTHER RECEIVABLES

[1] Pledges receivable:

At each fiscal-year-end, pledges receivable are estimated to be received as follows:

	June 30,	
	2025	2024
Less than one year	\$ 14,853,433	\$ 19,704,069
One to five years	7,683,333	15,566,666
Six to ten years	100,000	450,000
	22,636,766	35,720,735
Reduction of pledges due in excess of one year to present value, using discount rates ranging from 0.74% - 4.85%	(916,187)	(1,779,190)
Less: allowance for doubtful collections	(418,358)	(164,000)
	\$ 21,302,221	\$ 33,777,545

The Foundation wrote-off uncollectible pledges receivable of approximately \$53,000 and \$118,000 in fiscal-years 2025 and 2024, respectively.

[2] Other receivables:

Other receivables consist of accrued interest and other amounts due to the Foundation. All amounts are fully collectible within one year, and accordingly, no allowance for doubtful accounts or present value discount has been established.

THE BREAST CANCER RESEARCH FOUNDATION, INC.

Notes to Financial Statements June 30, 2025 and 2024

NOTE C - INVESTMENTS AND PROGRAM-RELATED INVESTMENTS

At each fiscal year-end, investments consisted of the following:

	June 30,			
	2025		2024	
	Fair Value	Cost	Fair Value	Cost
Cash and cash equivalents	\$ 2,168,197	\$ 2,168,197	\$ 1,325,151	\$ 1,325,151
Corporate bonds	8,763,177	8,796,267	8,383,534	8,601,710
Government obligations	50,050,317	49,236,234	48,103,984	47,628,830
Mutual funds - equity	44,580,379	29,086,669	30,703,064	19,081,226
Non-readily-marketable securities	999,991	999,991	-	-
	\$ 106,562,061	\$ 90,287,358	\$ 88,515,733	\$ 76,636,917

At June 30, 2025 and 2024, concentrations of the Foundation's investments in excess of 10% of the fair value of its portfolio included approximately 23% and 21%, respectively, invested in one equity mutual fund.

During each fiscal year, investment returns consisted of the following:

	Year Ended	
	June 30,	
	2025	2024
Interest and dividends	\$ 6,359,463	\$ 5,908,527
Realized gains/(losses)	1,118,063	(4,262,281)
Unrealized gains	4,395,887	8,305,445
Investment advisory fees	(128,475)	(114,649)
	\$ 11,744,938	\$ 9,837,042

The FASB's ASC Topic 820, *Fair Value Measurements*, establishes a three-level valuation hierarchy of fair-value designations. These valuation techniques are based on observable and unobservable inputs. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions. These two types of inputs create the following fair-value hierarchy:

- Level 1: Valuations are based on observable inputs that reflect quoted market prices in active markets for identical investments at the reporting date.
- Level 2: Valuations are based on: (i) quoted prices for similar investments in active markets; or (ii) quoted prices for those investments, or similar investments, in markets that are not active; or (iii) pricing inputs other than quoted prices that are directly or indirectly observable at the reporting date.

THE BREAST CANCER RESEARCH FOUNDATION, INC.

Notes to Financial Statements June 30, 2025 and 2024

NOTE C - INVESTMENTS AND PROGRAM-RELATED INVESTMENTS (CONTINUED)

Level 3: Valuations are based on pricing inputs that are unobservable and include situations where: (i) there is little, if any, market activity for the investments; or (ii) the investments cannot be independently valued.

The availability of market data is monitored to assess the appropriate classification of financial instruments within the fair-value hierarchy. Changes in economic conditions or valuation techniques may require the transfer of financial instruments from one fair-value level to another. In such instances, the transfer is reported at the beginning of the reporting period.

The following tables summarize the fair values of the Foundation's investments at each fiscal year-end in accordance with the ASC Topic 820 valuation levels:

	June 30, 2025			Total
	Level 1	Level 2	Level 3	
Cash and cash equivalents	\$ 2,168,197	\$ -	\$ -	\$ 2,168,197
Corporate bonds	-	8,763,177	-	8,763,177
Government obligations	49,776,928	273,389	-	50,050,317
Mutual funds - equity	44,580,379	-	-	44,580,379
Non-readily-marketable securities	-	-	999,991	999,991
	<u>\$ 96,525,504</u>	<u>\$ 9,036,566</u>	<u>\$ 999,991</u>	<u>\$ 106,562,061</u>

	June 30, 2024		
	Level 1	Level 2	Total
Cash and cash equivalents	\$ 1,325,151	\$ -	\$ 1,325,151
Corporate bonds	-	8,383,534	8,383,534
Government obligations	48,103,984	-	48,103,984
Mutual funds - equity	30,703,064	-	30,703,064
	<u>\$ 80,132,199</u>	<u>\$ 8,383,534</u>	<u>\$ 88,515,733</u>

During the fiscal-year ended June 30, 2025, the Foundation purchased \$999,991 of program-related non-readily-marketable securities which are considered Level 3 investments. (See Note J).

THE BREAST CANCER RESEARCH FOUNDATION, INC.

Notes to Financial Statements June 30, 2025 and 2024

NOTE C - INVESTMENTS AND PROGRAM-RELATED INVESTMENTS (CONTINUED)

The following table lists investment redemption terms as of June 30, 2025:

	<u>Fair Value</u>	<u>Unfunded Commitments</u>	<u>Redemption Frequency</u>	<u>Redemption Notice Period</u>
Non-readily-marketable securities:				
Preferred Stock	\$ 999,991	None	Following deemed liquidity event	N/A

The following provides information on the valuation techniques and nature of significant unobservable inputs used to determine the value of the Level 3 asset as of June 30, 2025:

	<u>Valuation Technique</u>	<u>Fair Value</u>	<u>Unobservable Inputs</u>	<u>Range of Inputs</u>
Preferred Stock	Market Approach	\$ 999,991	Consensus pricing	\$ 14.83

NOTE D - PROPERTY AND EQUIPMENT

At each fiscal-year-end, property and equipment consisted of the following:

	<u>June 30,</u>	
	<u>2025</u>	<u>2024</u>
Leasehold improvements	\$ 596,015	\$ 527,049
Furniture and equipment	594,779	579,320
	1,190,794	1,106,369
Less: accumulated depreciation and amortization	(793,374)	(664,437)
	\$ 397,420	\$ 441,932

THE BREAST CANCER RESEARCH FOUNDATION, INC.

**Notes to Financial Statements
June 30, 2025 and 2024**

NOTE E - GRANTS PAYABLE

At each fiscal-year-end, grants payable are due to be paid as follows:

	June 30,	
	2025	2024
Less than one year	\$ 71,993,816	\$ 64,611,208
One to five years	7,625,000	5,625,000
Six to ten years	3,375,000	4,500,000
	82,993,816	74,736,208
Reduction of pledges due in excess of one year to present value, using discount rates ranging ranging from 3.74% to 4.22%	(2,066,115)	(2,262,436)
	\$ 80,927,701	\$ 72,473,772

NOTE F - NET ASSETS WITH DONOR RESTRICTIONS

At each fiscal year-end, net assets with donor restrictions consisted of the following:

	June 30,	
	2025	2024
Purpose restrictions:		
Research grants	\$ 11,375,513	\$ 12,959,782
Clinical trials	1,500,000	1,864,463
	12,875,513	14,824,245
Subject to appropriation:		
Accumulated endowment earnings reserved for appropriation	2,166,634	1,546,761
Total purpose restrictions	15,042,147	16,371,006
Time-restricted for future periods	11,941,986	22,667,546
Perpetual in nature	8,563,341	8,540,747
	\$ 35,547,474	\$ 47,579,299

THE BREAST CANCER RESEARCH FOUNDATION, INC.

Notes to Financial Statements June 30, 2025 and 2024

NOTE F - NET ASSETS WITH DONOR RESTRICTIONS (CONTINUED)

During each fiscal-year, net assets released from restrictions, as the result of satisfying donor restrictions, were as follows:

	June 30,	
	2025	2024
Purpose restrictions satisfied as follows:		
Research grants	\$ 2,012,435	\$ 2,391,834
Clinical trials	364,463	2,268,661
	<u>2,376,898</u>	<u>4,660,495</u>
Time-restrictions satisfied	<u>16,125,189</u>	<u>5,109,489</u>
	<u>\$ 18,502,087</u>	<u>\$ 9,769,984</u>

NOTE G - CONDITIONAL COMMITMENT RECEIVED

In December 2019, the Foundation received a conditional grant of \$5,000,000 to establish a research fund. The Foundation has recognized \$4,877,143 of revenue from this grant through fiscal-year 2025, through satisfaction of the requisite conditions.

No provision for future amounts that may be received under this agreement has been included in the consolidated financial statements due to the conditional nature of the grant.

THE BREAST CANCER RESEARCH FOUNDATION, INC.

Notes to Financial Statements June 30, 2025 and 2024

NOTE H - DONATED GOODS AND SERVICES

The tables below disclose the in-kind donations received in each fiscal year, as well as the valuation techniques and inputs, the existence of donor restrictions, and the utilization in accordance with Accounting Standards Update (“ASU”) 2020-07:

Year Ended June 30, 2025

	Revenue Recognized	Utilization in Programs/Activities	Donor Restrictions	Valuation Techniques and Inputs
Donated media placements	\$ 4,914,393	Programmatic public awareness and education	None	Reflected at fair market value for rates that would be charged for equivalent placements.
Donated legal services	\$ 1,242,738	General and administrative	N/A	Contributed legal services are considered to reflect fair market rates for services performed.
Donated scientific consulting services	\$ 350,000	Program-related grant making	N/A	Contributed services from the Foundation's Scientific Advisory Committee are considered to reflect fair market rates for services performed.
Donated fund-raising merchandise	\$ 314,057	Provided to attendees at special events as tokens and raffle items	None	Reflected at market prices in the various principal markets where they are consumed.

Year Ended June 30, 2024

	Revenue Recognized	Utilization in Programs/Activities	Donor Restrictions	Valuation Techniques and Inputs
Donated legal services	\$ 765,000	General and administrative	N/A	Contributed legal services are considered to reflect fair market rates for services performed.
Donated scientific consulting services	\$ 480,000	Program-related grant making	N/A	Contributed services from the Foundation's Scientific Advisory Committee are considered to reflect fair market rates for services performed.
Donated fund-raising merchandise	\$ 149,558	Provided to attendees at special events as tokens and raffle items	None	Reflected at market prices in the various principal markets where they are consumed.

Other donated services:

A substantial number of Board members and volunteers have donated significant amounts of their time and support through fund-raising and participation in global events in furtherance of the Foundation's mission. Additionally, the Foundation is the benefactor of the net proceeds of a significant number of fund-raising events organized by outside, independent volunteers in the name of the Foundation. The value of this donated volunteer time is not reflected in the consolidated financial statements, as it does not meet the criteria for recognition under generally accepted accounting principles.

THE BREAST CANCER RESEARCH FOUNDATION, INC.

**Notes to Financial Statements
June 30, 2025 and 2024**

NOTE I - THE ENDOWMENT

[1] The endowment:

The Foundation's endowment consists of six donor-restricted funds, with the income earned thereon to be used for their respective research initiatives. As required by generally accepted accounting principles, net assets associated with the endowment fund are classified and reported based on the existence or absence of donor-imposed restrictions.

[2] Interpretation of relevant law:

NYPMIFA is applicable to all of the Foundation's institutional funds, including its donor-restricted endowment funds. The Board of Directors adheres to NYPMIFA's requirements.

[3] Endowment net-asset composition by type of fund, at each fiscal year-end:

	June 30, 2025		
	Amounts Subject to Appropriation	Amounts Held in Perpetuity	Total
Donor-restricted endowment funds	\$ 2,166,634	\$ 8,563,341	\$ 10,729,975

	June 30, 2024		
	Amounts Subject to Appropriation	Amounts Held in Perpetuity	Total
Donor-restricted endowment funds	\$ 1,546,761	\$ 8,540,747	\$ 10,087,508

THE BREAST CANCER RESEARCH FOUNDATION, INC.

**Notes to Financial Statements
June 30, 2025 and 2024**

NOTE I - THE ENDOWMENT (CONTINUED)

[3] Endowment net-asset composition by type of fund, at each fiscal year-end: (continued)

	June 30, 2025		
	With Donor Restrictions		
	Amounts Subject to Appropriation	Amounts Held in Perpetuity	Total
Endowment net assets and the earnings thereon (including net pledges receivable of \$877,407), beginning of year	\$ 1,546,761	\$ 8,540,747	\$ 10,087,508
Contributions	-	22,594	22,594
Investment income, net	341,710	-	341,710
Net appreciation (realized and and unrealized)	706,330	-	706,330
Appropriation of endowment assets for expenditure	<u>(428,167)</u>	<u>-</u>	<u>(428,167)</u>
Endowment net assets and the earnings thereon (including net pledges receivable of \$550,000), end of year	<u>\$ 2,166,634</u>	<u>\$ 8,563,341</u>	<u>\$ 10,729,975</u>
	June 30, 2024		
	With Donor Restrictions		
	Amounts Subject to Appropriation	Amounts Held in Perpetuity	Total
Endowment net assets and the earnings thereon, beginning of year	\$ 932,539	\$ 7,185,505	\$ 8,118,044
Contributions	-	1,355,242	1,355,242
Investment income, net	189,060	-	189,060
Net appreciation (realized and and unrealized)	784,437	-	784,437
Appropriation of endowment assets for expenditure	<u>(359,275)</u>	<u>-</u>	<u>(359,275)</u>
Endowment net assets and the earnings thereon (including net pledges receivable of \$877,407), end of year	<u>\$ 1,546,761</u>	<u>\$ 8,540,747</u>	<u>\$ 10,087,508</u>

THE BREAST CANCER RESEARCH FOUNDATION, INC.

Notes to Financial Statements June 30, 2025 and 2024

NOTE I - THE ENDOWMENT (CONTINUED)

[4] Return objectives and risk parameters:

The Foundation's endowment assets are invested in a manner intended to produce a positive return on invested assets, while assuming a moderate level of investment risk. Actual returns in any given year may vary, depending on investment strategies and economic conditions.

[5] Strategies employed for achieving objectives:

To satisfy its long-term rate-of-return objectives, the Foundation's Board of Directors relies on a total-return strategy in which investment returns are achieved through both capital appreciation (realized and unrealized) and current yield (interest and dividends).

[6] Spending policy:

The Foundation's Board of Directors has a policy for appropriating for each year an amount that shall not exceed an amount earned on the endowment. Over the long term, management expects the assets underlying its endowment to grow at a reasonable rate, consistent with the Board's objective to maintain the purchasing power of the endowment assets, as well as to provide additional real growth through new gifts and investment returns. During both fiscal-years 2025 and 2024, the spend rate was 5%, to ensure compliance with the spending requirements of the underlying gift agreements.

[7] Funds with deficiencies:

Due to unfavorable market fluctuations, from time-to-time, the fair value of assets associated with individual donor-restricted endowment funds may decline below the historical dollar value of the donor's original restricted contribution, or the amount required to be maintained under state law, referred to as underwater endowment. Under the terms of NYPMIFA, the Foundation has no responsibility to restore such decreases in value. At June 30, 2025 and 2024, there were no deficiencies of this nature.

NOTE J - BCRF VENTURES LLC

BCRF Ventures LLC ("Ventures") was established to facilitate mission-aligned investments that support the Foundation's exempt purpose. Through Ventures, the Foundation plans to make program-related investments in privately held entities whose activities are expected to advance breast cancer research, innovation or related charitable objectives. Such investments are not intended to generate significant income or appreciation of capital, and any potential financial return is incidental to the achievement of programmatic outcomes. At June 30, 2025, the Foundation invested approximately \$1,000,000 in non-readily-marketable securities towards this initiative. (See Note C). Subsequent to June 30, 2025, in November 2025, the Foundation purchased approximately \$1,000,000 of the same securities.

THE BREAST CANCER RESEARCH FOUNDATION, INC.

Notes to Financial Statements June 30, 2025 and 2024

NOTE K - RETIREMENT PLANS

[1] Defined-contribution retirement plan:

The Foundation participates in the Insperity 401(k) Plan, which is administered and maintained by the Foundation's third-party professional-service organization. The Plan is covered under Section 401(k) of the Code and covers all eligible employees, whereby it provides a matching contribution of up to 5% of an employee's annual compensation and up to 5% in a discretionary contribution. The Foundation's contributions to the Plan for fiscal-years 2025 and 2024 were approximately \$761,000 and \$698,000, respectively.

[2] Deferred compensation 457(b) retirement plan:

In fiscal-year 2024, the Foundation established a nonqualified deferred compensation plan (the "Plan") under Section 457(b) of Code for eligible employees. This Plan allows eligible participants to defer a portion of their salary and receive tax-deferred growth on their accumulated balances. The assets of the Plan are held by a third-party custodian. At June 30, 2025 and 2024, the Foundation maintained approximately \$369,000 and \$300,000, respectively, as both an asset and liability in the accompanying consolidated statements of financial position. Contributions to the Plan during fiscal-years 2025 and 2024 were approximately \$33,000 and \$47,000, respectively. Additionally, upon establishment of the Plan, the President of the Foundation transferred assets from an unrelated plan into the Foundation's Plan account. The assets of the Plan are invested in Level 1 investments as defined by ASC Topic 820.

NOTE L - RELATED-PARTY TRANSACTIONS

One of the Co-Chairs of the Foundation's Board of Directors is also the Chairman of the Board of Directors of The Estee Lauder Companies, Inc. ("ELC"), which donated a portion of its sales revenue to the Foundation and held various fund-raising events for the benefit of the Foundation. For fiscal-years 2025 and 2024, the Foundation recognized contribution revenue from ELC of approximately \$6,766,000 and \$7,695,000, respectively. During fiscal-years 2025 and 2024, certain directors of ELC also made personal contributions to the Foundation totaling approximately \$3,060,000 and \$3,577,000, respectively. Additionally, during fiscal-years 2025 and 2024, ELC donated items to be given away during the Foundation's fund-raising events valued at approximately \$86,000 and \$69,000, respectively.

NOTE M - CONCENTRATION OF PUBLIC SUPPORT AND REVENUE

During fiscal-year 2025, the Foundation received approximately 12% of its total public support and revenue from one donor. There were no such concentrations in fiscal-year 2024.

THE BREAST CANCER RESEARCH FOUNDATION, INC.

**Notes to Financial Statements
June 30, 2025 and 2024**

NOTE N - COMMITMENTS AND CONTINGENCY

[1] Lease obligations:

The Foundation is obligated under a non-cancelable operating lease agreement for office space, which was amended on July 1, 2022 to extend the lease through June 2028. In conjunction with this amendment, the Foundation received a rent holiday of six months and a tenant improvement allowance of \$370,450. Additionally, the Foundation leased additional space under the existing lease agreement, as amended, for a period of one-year expiring June 30, 2026, with two renewal options through June 30, 2027.

As of June 30, 2025 and 2024, the estimated future minimum annual lease payments under the lease described above are as follows:

Year Ending June 30,	2025	2024
2025	\$ -	\$ 740,900
2026	740,900	740,900
2027	740,900	740,900
2028	740,900	740,900
	2,222,700	2,963,600
Less: amount representing interest	(9,437)	(16,880)
Amount reported on the consolidated statements of financial position	\$ 2,213,263	\$ 2,946,720

The table below presents additional information related to the Foundation's leases for the year ended June 30, 2025 and 2024:

	2025	2024
Weighted average remaining lease term:		
Operating lease	3 years	4 years
Weighted average discount rate:		
Operating lease	2.92%	2.92%

The Foundation also leases storage space on a month-to-month basis.

THE BREAST CANCER RESEARCH FOUNDATION, INC.

Notes to Financial Statements June 30, 2025 and 2024

NOTE N - COMMITMENTS AND CONTINGENCY (CONTINUED)

[2] Government-funded activities:

The Foundation received funds under the Paycheck Protection Program (the "PPP"). Substantially all of the PPP loan was forgiven, with the remaining balance being converted to a term loan, which was repaid in full in August 2023. The U.S. Small Business Administration ("SBA") may, at its discretion, audit any PPP loan for up to six years after the date the loan was forgiven. The SBA reserves the right to audit PPP loans of any size, and such audits may occur after forgiveness has been granted. In accordance with the CARES Act, borrowers are required to retain PPP loan documentation for six years after the loan is forgiven or repaid in full and to provide such documentation to the SBA upon request.

[3] Employment agreement:

The Foundation is obligated under an employment agreement with its President through March 31, 2026. Subsequent to year-end, the agreement automatically renewed through March 31, 2028.

[4] Payroll:

The Foundation leases its employees from a third-party, professional service organization, under an agreement which automatically renews on an annual basis, unless terminated with notice by either party.

[5] Future fund-raising events:

The Foundation is obligated under various rental agreements for fund-raising events to be held subsequent to fiscal year-end, the deposits for which have been reported as prepaid expenses in the consolidated statements of financial position.

[6] Other contracts:

In the normal course of business, the Foundation enters into various contracts and agreements for professional and other services, which are typically renewed on a year-to-year basis.

NOTE O - CONCENTRATION OF CREDIT RISK

The Foundation maintains its cash and cash equivalents in accounts with balances that frequently exceed federally insured limits. The Foundation has not experienced any losses in such accounts, and management monitors the risk associated with concentrations on an on-going basis. Management believes that the Foundation does not face a significant risk of loss that might result from the failure of these financial institutions.

THE BREAST CANCER RESEARCH FOUNDATION, INC.

Notes to Financial Statements June 30, 2025 and 2024

NOTE P - LIQUIDITY AND AVAILABILITY OF RESOURCES

The following reflects the Foundation's financial assets available for general expenditure (which includes scheduled grant payments) as of the consolidated statements of financial position date, reduced by amounts not available for general use within one year because of donor-imposed restrictions:

	June 30,	
	2025	2024
Cash and cash equivalents	\$ 89,082,207	\$ 72,935,937
Pledges receivable, net	21,302,221	33,777,545
Other receivables	562,235	788,347
Investments	105,562,070	88,515,733
	<u>216,508,733</u>	<u>196,017,562</u>
Total financial assets available within one year		
Less:		
Amounts unavailable for general expenditures within one year, due to:		
Restrictions by donors with purpose restrictions	(15,042,147)	(16,371,006)
Restrictions by donors for future periods	(11,941,986)	(22,667,546)
Restrictions by donors that are perpetual in nature	(8,563,341)	(8,540,747)
	<u>(35,547,474)</u>	<u>(47,579,299)</u>
Total amounts unavailable for general expenditure within one year		
Total financial assets available to meet cash needs for general expenditures within one year	<u>\$ 180,961,259</u>	<u>\$ 148,438,263</u>

Liquidity policy:

The Foundation's fiscal policies are structured to ensure that sufficient financial assets are available as its general expenditures, liabilities, and other obligations come due. The Foundation meets this objective primarily through its current policy to approve research grants for funding after the funds have been raised, as well as maintaining a minimum of one year of operating (non-grant) expenses in reserves. The Foundation maintains a significant balance of cash and cash equivalents at each fiscal-year end due to funding requirements of committed research payments that are to be paid soon after each fiscal year-end.

NOTE Q - SUBSEQUENT EVENTS

The Foundation has evaluated subsequent events through May 6, 2026, the date on which the consolidated financial statements were available to be issued.